The positive Phase 3 data significantly de-risks the ALXN1840 program and increases the probability of FDA approval. This could lead to substantial revenue growth if approved, making this a key catalyst for the stock. Monitor for upcoming regulatory interactions with FDA.
Price Chart
Executive Summary
Monopar Therapeutics announced positive Phase 3 clinical trial data showing ALXN1840 demonstrated greater neurologic benefit versus standard of care in Wilson disease patients with neurologic symptoms. The data supports the planned New Drug Application submission to the FDA in mid-2026.
Key Facts
- New Phase 3 data shows ALXN1840 provided greater neurologic improvement and significantly less worsening than standard of care in Wilson disease patients
- Data presented at American Academy of Neurology (AAN) Annual Meeting 2026
- Findings support planned New Drug Application (NDA) submission to FDA in mid-2026
- ALXN1840 has favorable safety profile with drug-related serious adverse events limited to 4.9% of patients
Financial Impact
Potential approval and commercialization of ALXN1840 for Wilson disease
Risk Factors
- Regulatory approval is not guaranteed
- Potential competition from other Wilson disease treatments
- Clinical trial results may not translate to real-world effectiveness
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-012751 |
| Exhibit: ex_947617.htm | 0001437749-26-012751 |
| Document: 0001437749-26-012751-index-headers.html | 0001437749-26-012751 |
| Document: 0001437749-26-012751-index.html | 0001437749-26-012751 |
| Document: 0001437749-26-012751.txt | 0001437749-26-012751 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 27, 2026 today | SC 13G | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 5, 2026 22d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $71.84 (+9.71%) |
Oct 1, 2026 26d ago | 144 | $77.97 | awaiting T+60 | — | $71.84 (−7.86%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $71.84 (−35.82%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $71.84 (−35.79%) |
Aug 25, 2026 9w ago | 144 | $113.72 | awaiting T+60 | — | $71.84 (−36.83%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $71.84 (−36.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers